BCRX
Biocryst Pharmaceuticals Inc
$10.45
-0.27 (-2.52%)
At close · Jul 10
Market Cap
$2.66B
Shares
254,162,660
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.45
Open$10.69
Day$10.28–10.72
52W$6.00–11.22
Avg vol 30d5.4M
Short int48.7M · 19.2% float · 6.0d
Short vol40%
Last earningsMay 6, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 6
Up next
Next earnings call
Jul 26, 2026
Est · unconfirmed
· in 2 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+29%
above
Price vs 50-day avg
+14%
above
RSI (14)
61
neutral
MACD trend
Positive
52-week position
85%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+28%
trailing
6-month return
+46%
trailing
YTD return
+34%
this year
Relative strength
+37%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
7 of 302 funds reported for Jun 30 · net +501.6K sh shares · +2 new
Insider flow
Distributing
Net -$696.5K over 90 days · 100% sells
Short interest
Rising
19.16% of float · ▲ +19.8% MoM · 6.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
302 holders — near 3-yr high, broad support
Squeeze score
87
high risk · 0–100
Fundamentals
Revenue growth
−4%
Y/Y
EPS growth
+381%
Y/Y
Free cash flow
$347.0M
Balance sheet
$208.4M
net debt
Quant / Vol
risk profile
Volatility
46%
annualized · 1-yr
Max drawdown
−30%
past year
ATR
5.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 6, 2026
Non-GAAP operating expenses, excluding stock-based compensation,
· full year 2026
Non-GAAP
Initiated
$450M – $470M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+29%
Bullish
Price vs 50-day avg
+14%
Bullish
RSI (14)
61
Neutral
MACD trend
Positive
Bullish
52-week position
85%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $9 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
7 of 302 funds reported for Jun 30 · net +501.6K sh shares · +2 new
Insider flow
Distributing
Net -$696.5K over 90 days · 100% sells
Short interest
Rising
19.16% of float · ▲ +19.8% MoM · 6.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
302 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $6
Now $10 · 85%
52-wk high $11
vs 200-day avg +29%
vs 50-day avg +14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents, restricted cash & investments | $338M | as of December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BCRX
this stock
Biocryst Pharmaceuticals Inc
|
$2.66B | +34.0% | -4.4% | — | 19.2% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$52.88B | +6.2% | — | — | 0.2% |
|
GALDY
Galderma Group AG/ADR
|
$50.15B | +3.2% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$42.98B | -3.5% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BCRX | +6.2% | +27.6% | +45.8% | +4.5% | +34.0% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | +4.8% | +23.5% | +36.7% | +3.4% | +23.3% |